The US Food and Drug Administration (FDA) has approved denosumab (Prolia) as a treatment, for the following indications:

• to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer, and

• as a treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for non-metastatic prostate cancer.